Can a new tetanus shot offer stronger protection?

NCT ID NCT07740733

Completed ⭐️ VACCINE ⭐️ Sponsor: Beijing Minhai Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial is testing a new tetanus vaccine in healthy adults aged 18 to 43. The goal is to see if the vaccine is safe and triggers a strong immune response, measured by antibody levels one month after vaccination. Participants will receive either the new vaccine or a control vaccine, and their health and immune reactions will be compared.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tetanus toxoid (adsorbed) vaccine
What this could lead to: If successful, this could provide a new, safe, and effective tetanus vaccine option for adults, potentially improving protection against this serious bacterial infection.
What could go wrong: This is an early-to-mid-stage trial, so the vaccine may not produce a strong enough immune response or may cause unexpected side effects. Results from this trial will need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TETANUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tetanus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TETANUS TETANUS VACCINE

Contacts and locations

Locations

Guangdong Provincial Center for Diseases Control and Prevention

Guangzhou, Guangdong, 510440, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.